Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

BACKGROUND: Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activity with long-term stabilization. However, the benefits of the drug are countered by a risk of developing progressive multifocal leukoencephalopathy in patients infected with the John Cunningham Virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Gass, Achim, Wuerfel, Jens, Bayas, Antonios, Tackenberg, Björn, Limmroth, Volker, Linker, Ralf, Mäurer, Mathias, Haas, Judith, Stangel, Martin, Meergans, Matthias, Harlin, Olof, Hartung, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942949/
https://www.ncbi.nlm.nih.gov/pubmed/27405225
http://dx.doi.org/10.1186/s12883-016-0625-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942949/
https://www.ncbi.nlm.nih.gov/pubmed/27405225
http://dx.doi.org/10.1186/s12883-016-0625-0

Ejemplares similares